UBS Group’s Revolution Medicines RVMD Stock Holding History

UBS Group’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$729K	Buy	+7,500	New	+$757K	﹤0.01%	5797

Other funds holding RVMD

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

UBS Group's RVMD Position: Q1 2026 in Review

UBS Group increased its Revolution Medicines (RVMD) stake by 42% in Q1 2026, buying an estimated $131M and bringing the position to 4,386,791 shares worth $427M. The position accounts for 0.06% of the portfolio, ranked #308.

UBS Group first reported a position in RVMD in Q1 2020 and has held it in 24 quarters since. 512 funds tracked by Wall St. Rank hold RVMD as of Q1 2026.

UBS Group held 4,386,791 shares of Revolution Medicines worth $427M as of Q1 2026.
UBS Group bought 1,298,854 Revolution Medicines shares in Q1 2026, an estimated $131M.
Revolution Medicines made up 0.06% of UBS Group's portfolio in Q1 2026, its #308 holding.
UBS Group first reported a position in Revolution Medicines in Q1 2020 and has held it in 24 quarters since.
512 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.